# 2025年11月16日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 危重症后的随访由谁负责？来自全科医生、ICU医生和患者的观点

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41239502](https://pubmed.ncbi.nlm.nih.gov/41239502)
**期刊：** Critical care (London, England)
**PMID：** 41239502
**DOI：** 10.1186/s13054-025-05724-w

### 第一部分 原文与翻译

**英文原标题：** Who is responsible for follow-up after critical illness? GP, ICU and patient perspectives.

**英文摘要原文：**
BACKGROUND: Critical illness is associated with a range of physical, psychological, medical and social sequalae. It is unclear from existing clinical guidance who should be responsible for follow-up of these sequalae following hospital discharge.

AIM: To explore the views of views of UK general practitioners (GPs), intensive care medicine (ICM) consultants, and patients on responsibility for follow-up care for critical illness survivors following hospital discharge.

METHODS: Dual methods study based in the UK. Data were collected from UK ICM consultants, GPs and patients using online questionnaires, interviews, and focus groups. Analysis was informed by the Consolidated Framework for Implementation Research (CFIR).

RESULTS: There was a lack of clarity within and between groups on who is responsible for follow-up. We identified various potential explanations for the lack of consensus including variable awareness of critical illness survivorship, ambiguity within clinical guidelines, lack of clarity on the boundaries of critical illness morbidity, evolving roles of healthcare providers, and significant workload and resource pressures within the UK healthcare system.

CONCLUSION: The experiences of healthcare professionals and patients indicate the current lack of clarity could negatively impacting patient care and outcomes. Consensus is required on how we should define the boundaries of critical illness sequalae, and which clinical groups are responsible for care across the various transitions of care experienced by intensive care unit (ICU) survivors.

**中文摘要译文：**
背景：危重症与一系列生理、心理、医疗和社会后遗症相关。现有临床指南并未明确出院后应由谁负责对这些后遗症进行随访。

目的：旨在探究英国家庭医生（GPs）、重症监护医学（ICM）顾问医生以及患者对于危重症幸存者出院后随访护理责任的看法。

方法：本研究为在英国进行的一项双方法研究。通过在线问卷、访谈和焦点小组从英国重症监护医学顾问医生、家庭医生和患者中收集数据。分析采用了实施研究综合框架（CFIR）。

结果：各组内部及组间对于随访责任归属均缺乏明确认识。我们识别出导致这种共识缺失的多种可能原因，包括对危重症生存状态的认知差异、临床指南的模糊性、危重症病损边界的不明确、医疗服务提供者角色的演变，以及英国医疗系统内显著的工作量和资源压力。

结论：医护人员和患者的经历表明，当前责任归属的不明确可能对患者的护理和结局产生负面影响。我们需要就如何界定危重症后遗症的范围，以及在重症监护室（ICU）幸存者经历的各种医疗照护过渡阶段中，应由哪些临床团队负责，达成共识。

### 第二部分 AI 大师评价

该研究通过在线问卷、访谈和焦点小组等多种方法，创新性地从全科医生、ICU医生和患者三个关键视角，系统探讨了危重症患者出院后随访责任归属这一核心问题。研究明确揭示了当前临床实践中普遍存在的责任不明确现象，并深入分析了其背后的多重原因，如指南模糊、资源压力等。此项研究的价值在于，它不仅指出了当前危重症患者照护连续性中的一个关键断点，更为推动制定清晰的临床指南和优化医疗服务流程提供了直接的证据支持，对改善患者长期预后具有重要的临床和政策意义。

---

## 2. 急性早幼粒细胞白血病患者的早期死亡率：一项系统评价与荟萃分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41239429](https://pubmed.ncbi.nlm.nih.gov/41239429)
**期刊：** Critical care (London, England)
**PMID：** 41239429
**DOI：** 10.1186/s13054-025-05743-7

### 第一部分 原文与翻译

**英文原标题：** Early mortality in patients with acute promyelocytic leukemia: a systematic review and meta-analysis.

**英文摘要原文：**
BACKGROUND: In patients with acute promyelocytic leukemia (APL), early mortality, defined as death within 30 days following diagnosis, is the main driver of overall survival. Intensivists play a pivotal role in the management of patients with APL.

METHOD: The PubMed and Embase databases were searched on December 1, 2023. All studies focusing on early mortality in patients with newly diagnosed APL were included. Two reviewers independently selected the studies and assessed bias using the risk-of-bias 2 scale for randomized controlled trials (RCT) and the Newcastle-Ottawa scale for other types of studies. A meta-analysis using a random effects model was performed. The primary outcome was early mortality. A subgroup analysis was performed to assess the differences between interventional and observational studies. Secondary outcomes included reasons for early mortality and the occurrence of severe hemorrhage or differentiation syndrome (DS).

RESULTS: Of the 950 studies screened, 140 met the inclusion criteria. A total of 54,923 patients newly diagnosed with APL were included in the meta-analysis. A meta-analytical early mortality rate of 12% was calculated across 122 studies. Early mortality was lower in interventional studies (8%) than in observational studies (15%). Hemorrhage was the main cause of early mortality (57%), followed by sepsis (18%), DS (12%), and thrombotic events (2%). In a meta-regression, early mortality was influenced by patients' age, white blood cell count at diagnosis, time, study type, and country of origin according to income classification.

CONCLUSION: There is an encouraging decrease over time of early mortality in patients with APL. Early mortality is lower in interventional studies. This result reflects the difficulty of translating the successes of RCT and interventional research into real-world clinical practice. This study puts forward the need to improve and standardize early management, notably in the intensive care unit.

TRIAL REGISTRATION: This study's protocol was preregistered on PROSPERO (CRD42023488480).

**中文摘要译文：**
背景：在急性早幼粒细胞白血病（APL）患者中，定义为诊断后30天内死亡的早期死亡是影响总生存率的主要因素。重症监护医师在APL患者的管理中扮演着关键角色。

方法：于2023年12月1日检索了PubMed和Embase数据库。所有关注新诊断APL患者早期死亡率的研究均被纳入。两名评价员独立筛选研究，并使用偏倚风险评估工具第二版（risk-of-bias 2 scale）评估随机对照试验（RCT）的偏倚，使用纽卡斯尔-渥太华量表（Newcastle-Ottawa scale）评估其他类型研究的偏倚。采用随机效应模型进行荟萃分析。主要结局指标是早期死亡率。进行亚组分析以评估干预性研究与观察性研究之间的差异。次要结局指标包括早期死亡原因以及严重出血或分化综合征（DS）的发生情况。

结果：在筛选的950项研究中，有140项符合纳入标准。荟萃分析共纳入54,923名新诊断的APL患者。综合122项研究计算得出，荟萃分析的早期死亡率为12%。干预性研究中的早期死亡率（8%）低于观察性研究（15%）。出血是早期死亡的主要原因（57%），其次是脓毒症（18%）、分化综合征（12%）和血栓事件（2%）。在荟萃回归分析中，早期死亡率受患者年龄、诊断时白细胞计数、时间、研究类型以及根据收入分类的国家来源的影响。

结论：APL患者的早期死亡率随时间推移呈现出令人鼓舞的下降趋势。早期死亡率在干预性研究中更低。这一结果反映了将随机对照试验和干预性研究的成功经验转化为真实世界临床实践的困难。本研究提出，有必要改进和规范早期管理，尤其是在重症监护室中的管理。

试验注册：本研究方案已在PROSPERO预先注册（CRD42023488480）。

### 第二部分 AI 大师评价

该研究通过大规模的系统回顾与荟萃分析，全面评估了急性早幼粒细胞白血病（APL）患者的早期死亡率。其核心发现揭示了临床试验环境（死亡率8%）与真实世界临床实践（死亡率15%）之间的显著差距，并明确指出出血是导致早期死亡的首要原因。这项研究的价值在于，它不仅量化了这一转化医学中的关键难题，还强调了规范化早期管理，特别是重症监护，对于改善患者预后的迫切性，为优化APL治疗策略提供了高级别证据支持。

---

## 3. 以大语言模型驱动的指南依从性增强呼吸支持预测模型

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41239417](https://pubmed.ncbi.nlm.nih.gov/41239417)
**期刊：** Critical care (London, England)
**PMID：** 41239417
**DOI：** 10.1186/s13054-025-05739-3

### 第一部分 原文与翻译

**英文原标题：** Enhancing predictive modeling for respiratory support with LLM-driven guideline adherence.

**英文摘要原文：**
BACKGROUND: Optimal respiratory support selection between high-flow nasal cannula (HFNC) and noninvasive ventilation (NIV) for intensive care units (ICU) patients at risk of invasive mechanical ventilation (IMV) remains unclear, particularly in cases not represented in prior clinical trials. We previously developed RepFlow-CFR, a deep counterfactual model estimating individualized treatment effects (ITE) of HFNC versus NIV. However, interpretability and guideline alignment remain challenges for clinical adoption. This study describes the development and integration of a clinical guideline-driven LLM to enhance deep counterfactual model recommendations for NIV versus HFNC in patients at high-risk for invasive mechanical ventilation.

METHODS: We enhanced RepFlow-CFR by incorporating a large language model (LLM, Claude 3.5 Sonnet) to enforce clinical guideline adherence and generate explainable treatment recommendations. The LLM was configured in a HIPAA-compliant AWS environment and prompted using structured patient data, clinical notes, and formal guideline criteria. Recommendations from RepFlow-CFR and LLM were compared to actual treatment decisions to assess concordance. We evaluated IMV and mortality/hospice rates across concordant and discordant groups. Additionally, we conducted a structured chart review of 20 cases to assess the clinical validity and safety of LLM-driven recommendations.

RESULTS: Among 1,261 ICU encounters, treatments concordant with LLM-enhanced recommendations were associated with lower IMV rates. For the HFNC recommendation, IMV occurred in 46/188 (24.47%) when care was concordant versus 9/17(52.94%) when discordant, corresponding to a 97.33% relative risk increase when discordant. Concordance was also associated with reduced mortality or hospice discharge (odds ratio 0.670, p = 0.046). In a 20-case chart review, 19/20 (95%) LLM recommendations aligned with clinical guidelines and physicians agreed with 13/20 (65%) final recommendations. Errors were noted in 11/20 cases, most rated low or moderate risk; 2/20 were judged as potentially causing severe harm.

CONCLUSIONS: Integrating LLMs for guideline enforcement improves the interpretability and clinical alignment of counterfactual models in respiratory support decision-making. This hybrid framework not only enhances concordance with real-world practice but may also improve patient outcomes. Future work will refine contraindication detection and expand validation to prospective clinical trials.

**中文摘要译文：**
背景：对于有创机械通气（IMV）风险的重症监护室（ICU）患者，在高流量鼻导管（HFNC）和无创通气（NIV）之间的最佳呼吸支持选择仍不明确，尤其是在以往临床试验中未被代表的病例中。我们先前开发了RepFlow-CFR，这是一个深度反事实模型，用于评估HFNC与NIV的个体化治疗效果（ITE）。然而，可解释性和指南一致性仍然是其临床应用的挑战。本研究描述了一个由临床指南驱动的大型语言模型（LLM）的开发与整合过程，旨在为高危有创机械通气风险患者增强深度反事实模型关于NIV与HFNC的推荐。

方法：我们通过整合一个大型语言模型（LLM, Claude 3.5 Sonnet）来增强RepFlow-CFR，以强制执行临床指南依从性并生成可解释的治疗建议。该LLM被配置在符合HIPAA标准的AWS环境中，并使用结构化的患者数据、临床记录和正式的指南标准进行提示。我们将RepFlow-CFR和LLM的建议与实际治疗决策进行比较，以评估其一致性。我们评估了一致组和不一致组之间的IMV率以及死亡率/临终关怀率。此外，我们对20个病例进行了结构化图表审查，以评估LLM驱动建议的临床有效性和安全性。

结果：在1,261次ICU就诊中，与LLM增强建议一致的治疗与更低的有创机械通气率相关。对于HFNC建议，当治疗一致时，IMV发生率为46/188（24.47%），而当治疗不一致时为9/17（52.94%），这对应于不一致时相对风险增加了97.33%。一致性还与死亡率或转入临终关怀的减少相关（比值比 0.670, p = 0.046）。在20例病例的图表审查中，19/20（95%）的LLM建议与临床指南一致，医生同意了13/20（65%）的最终建议。在11/20的病例中发现了错误，大多数被评为低或中度风险；2/20被判定可能导致严重伤害。

结论：整合LLM以执行指南，提高了反事实模型在呼吸支持决策中的可解释性和临床一致性。这种混合框架不仅增强了与真实世界实践的一致性，还可能改善患者结局。未来的工作将精炼禁忌症检测，并将验证扩展到前瞻性临床试验。

### 第二部分 AI 大师评价

本研究旨在解决深度学习模型在临床决策中可解释性不足和指南依从性难以保证的核心痛点。研究创新性地将深度反事实模型（RepFlow-CFR）与大语言模型（LLM）相结合，创建了一个混合AI框架，用于优化ICU患者呼吸支持方式（HFNC vs. NIV）的选择。关键发现表明，遵循该增强型模型的建议与更低的有创机械通气率和死亡率相关，验证了该方法改善患者结局的潜力。尽管研究指出了LLM在推荐中仍存在错误风险，但其为实现更安全、可信、且与临床实践紧密结合的AI决策支持系统提供了极具价值的范例和发展方向。

---

## 4. 危重症成人机械通气患者的吸入性镇静：在可持续性方面，并非所有镇静剂都等同！

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41239410](https://pubmed.ncbi.nlm.nih.gov/41239410)
**期刊：** Critical care (London, England)
**PMID：** 41239410
**DOI：** 10.1186/s13054-025-05671-6

### 第一部分 原文与翻译

**英文原标题：** Volatile sedation in critically ill adults undergoing mechanical ventilation: not all sedatives are equivalent, in sustainability!

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献标题表明，这可能是一篇评论或观点性文章，而非原创性研究。文章的核心主张是，在为接受机械通气的危重症患者选择镇静药物时，除了考虑临床效果，还必须评估其对环境的可持续性影响。作者特别强调，不同的镇静药物（尤其是吸入性镇静剂）在环境足迹方面存在显著差异。此文的价值在于将环境可持续性这一前沿概念引入重症监护领域的药物选择决策中，拓展了临床实践的考量维度，对推动绿色ICU理念具有重要意义。

---

## 5. 近红外光谱技术（NIRS）在动脉瘤性蛛网膜下腔出血中的神经监护应用：一项系统性综述与荟萃分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41239395](https://pubmed.ncbi.nlm.nih.gov/41239395)
**期刊：** Critical care (London, England)
**PMID：** 41239395
**DOI：** 10.1186/s13054-025-05701-3

### 第一部分 原文与翻译

**英文原标题：** Neuromonitoring with near-infrared spectroscopy (NIRS) in aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis.

**英文摘要原文：**
PURPOSE: Near-infrared spectroscopy (NIRS) is a non-invasive, real-time and continuous cerebral oximetry monitoring with potential applications in the management of aneurysmal subarachnoid hemorrhage (aSAH) and in the detection of delayed cerebral ischemia (DCI). The aim of this study was to evaluate the association between NIRS and outcome in aSAH and its diagnostic accuracy for DCI.

METHODS: Systematic review and meta-analysis of studies involving adult aSAH patients monitored with NIRS during index hospitalization. Primary outcome was the functional outcome at 90 days or more. Secondary outcomes included any functional outcome, mortality and diagnostic accuracy for DCI. Random effects meta-analyses were performed, and for diagnostic accuracy, forest plots and random effects meta-analyses were used to determine pooled sensitivity, specificity, diagnostic odds ratios and to generate a receiver operating characteristic (ROC) curve.

RESULTS: Of the 28,296 citations identified, 35 satisfied inclusion criteria. Three studies (202 patients) were included for meta-analysis of the primary outcome. Cerebral desaturation events or loss of autoregulation as detected with NIRS were associated with higher risks of unfavourable outcome at 90 days (RR 4.29 95% CI [2.10;8.79]). Significant associations were also observed with mortality (RR 4.24, 95% CI [2.43;7.41]). Diagnostic accuracy analysis demonstrated moderate sensitivity (0.85), specificity (0.65), and diagnostic odds ratio (10.42), with a receiver operating characteristic (ROC) curve area of 0.68. The certainty of evidence was moderate for the association between NIRS and patient outcomes, and low for its diagnostic accuracy in detecting DCI.The overall quality of evidence was limited by small sample sizes, high heterogeneity in study methods and patient populations, and potential publication bias.

CONCLUSION: Cerebral desaturation events and impaired autoregulation detected by NIRS are consistently associated with poor outcomes and mortality in aSAH. However, NIRS alone provides only moderate diagnostic accuracy for DCI, with a considerable risk of false positives. The evidence is weakened by methodological limitations, heterogeneous thresholds, and the absence of a universally accepted reference standard for DCI diagnosis. Importantly, no interventional data are available to demonstrate an effect on patient outcomes. While incorporation into multimodal neuromonitoring strategies appears promising, robust prospective trials are needed before NIRS can be reliably adopted in routine clinical practice.

**中文摘要译文：**
目的：近红外光谱技术（NIRS）是一种无创、实时、连续的脑氧饱和度监测技术，在动脉瘤性蛛网膜下腔出血（aSAH）的管理以及迟发性脑缺血（DCI）的检测中具有潜在应用价值。本研究旨在评估aSAH患者中NIRS与预后的关联及其对DCI的诊断准确性。

方法：对指数住院期间接受NIRS监测的成年aSAH患者研究进行系统性综述和荟萃分析。主要结局是90天或更长时间的功能性预后。次要结局包括任何功能性预后、死亡率以及对DCI的诊断准确性。研究采用随机效应模型进行荟萃分析，并针对诊断准确性，使用森林图和随机效应荟萃分析来确定合并的敏感性、特异性、诊断比值比，并生成受试者工作特征（ROC）曲线。

结果：在检索到的28,296篇引文中，35篇符合纳入标准。其中三项研究（共202名患者）被纳入主要结局的荟萃分析。NIRS检测到的脑氧饱和度下降事件或脑自动调节功能丧失与90天时不良功能预后的风险增加相关（RR 4.29, 95% CI [2.10;8.79]）。同时，也观察到其与死亡率存在显著关联（RR 4.24, 95% CI [2.43;7.41]）。诊断准确性分析显示，其敏感性（0.85）和特异性（0.65）中等，诊断比值比为10.42，受试者工作特征（ROC）曲线下面积为0.68。关于NIRS与患者预后关联的证据确定性为中等，而其检测DCI的诊断准确性证据确定性为低。证据的整体质量受到样本量小、研究方法和患者人群异质性高以及潜在发表偏倚的限制。

结论：NIRS检测到的脑氧饱和度下降事件和自动调节功能受损与aSAH患者的不良预后及死亡率持续相关。然而，单独使用NIRS对DCI的诊断准确性仅为中等水平，且存在相当大的假阳性风险。方法学局限、阈值异质以及缺乏公认的DCI诊断金标准削弱了该证据的强度。重要的是，目前尚无干预性研究数据证明其对患者预后有改善作用。尽管将NIRS纳入多模态神经监护策略前景广阔，但在其能够被可靠地应用于常规临床实践之前，仍需开展稳健的前瞻性试验。

### 第二部分 AI 大师评价

本研究通过系统性综述与荟萃分析，明确了近红外光谱技术（NIRS）在动脉瘤性蛛网膜下腔出血（aSAH）管理中的应用价值与局限。研究的核心发现是，NIRS监测到的脑氧饱和度下降事件与患者的不良预后和死亡率显著相关，证实了其作为预后指标的潜力。然而，研究也揭示了NIRS单独用于诊断迟发性脑缺血（DCI）的准确性仅为中等水平，存在较高的假阳性风险。此项工作为临床实践提供了重要参考，强调了将NIRS融入多模态监护的必要性，并指出了未来需要进行干预性研究以验证其对改善患者结局的实际效果。

---

## 6. 资源受限环境下的先进无创呼吸支持：一篇叙述性综述

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41239375](https://pubmed.ncbi.nlm.nih.gov/41239375)
**期刊：** Critical care (London, England)
**PMID：** 41239375
**DOI：** 10.1186/s13054-025-05688-x

### 第一部分 原文与翻译

**英文原标题：** Advanced non-invasive respiratory support in resource-constrained settings: a narrative review.

**英文摘要原文：**
Advanced non-invasive respiratory support techniques include high flow oxygen, continuous positive airway pressure, and non-invasive ventilation. Given their relative simplicity and lower resource intensity as compared with invasive mechanical ventilation, these mechanisms of respiratory support represent an attractive opportunity for use in patients with acute respiratory failure in resource-constrained settings. High flow oxygen in particular has the potential to provide high levels of respiratory support with relatively low levels of human and other resources to a wide variety of patients with respiratory failure, including those with delirium or obtundation. Even after the COVID-19 pandemic, during which utilization of these techniques increased in high-income countries, low and lower-middle income countries still have little access to advanced non-invasive respiratory support. Evidence from high-income countries and limited evidence from low-income countries suggest that these respiratory support methods may be particularly beneficial in resource-constrained settings; however, the evidence also suggests that the populations chosen and particularly the attention and resources invested in implementation are critical in ensuring the safety and effectiveness of non-invasive support. While non-invasive respiratory support does not require the complex training and monitoring needed for invasive support (e.g. specific risks associated with the endotracheal tube, sequelae of sedation, complex ventilator modes), it nonetheless requires resources in order to be applied effectively. Particular domains that need careful consideration are: clinical systems of care; oxygen consumption and connector compatibilities; human resources and training; location within the hospital; acceptability; cost; and device characteristics. In addition, ongoing research is needed that includes randomized controlled trials with attention to context, so that clinicians in resource-constrained settings can apply relevant evidence for non-invasive respiratory support for patients in their settings.

**中文摘要译文：**
先进的无创呼吸支持技术包括高流量氧疗、持续气道正压通气和无创通气。与有创机械通气相比，这些呼吸支持方式相对简单、资源强度较低，因此在资源受限环境下，它们为急性呼吸衰竭患者提供了一个有吸引力的治疗选择。特别是高流量氧疗，它有潜力以相对较少的人力和其他资源，为包括谵妄或意识模糊在内的多种呼吸衰竭患者提供高水平的呼吸支持。即使在COVID-19大流行之后（期间高收入国家对这些技术的使用有所增加），低收入和中低收入国家获得先进无创呼吸支持的机会仍然很少。来自高收入国家的证据以及来自低收入国家的有限证据表明，这些呼吸支持方法在资源受限环境下可能尤其有益；然而，证据也表明，选择合适的患者人群，尤其是在实施过程中投入的关注和资源，对于确保无创支持的安全性和有效性至关重要。虽然无创呼吸支持不像有创支持那样需要复杂的培训和监测（例如，与气管插管相关的特定风险、镇静后遗症、复杂的呼吸机模式），但要有效应用，它仍然需要一定的资源。需要仔细考虑的特定领域包括：临床照护体系、氧气消耗和接头兼容性、人力资源与培训、在医院内的部署位置、可接受性、成本以及设备特性。此外，还需要开展持续的研究，包括关注具体情境的随机对照试验，以便资源受限环境下的临床医生能够将相关的无创呼吸支持证据应用于他们所在环境的患者。

### 第二部分 AI 大师评价

本篇叙述性综述探讨了高流量氧疗等先进无创呼吸支持技术在资源受限环境下的应用前景与挑战。文章总结现有证据指出，这些技术因其简便性和较低的资源消耗，对急性呼吸衰竭患者极具吸引力，但其安全性和有效性高度依赖于实施策略、人员培训和资源配套。该综述虽非原创性研究，但通过系统梳理关键实施要素，为在资源匮乏地区推广这些救生技术提供了重要的实践指导，并强调了开展结合当地情境的临床试验的必要性，具有显著的临床指导价值和全球卫生意义。

---

## 7. 可转移性TMexCD1-TOprJ1外排泵的组装与抑制机制

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41238543](https://pubmed.ncbi.nlm.nih.gov/41238543)
**期刊：** Nature communications
**PMID：** 41238543
**DOI：** 10.1038/s41467-025-65038-x

### 第一部分 原文与翻译

**英文原标题：** Assembly and inhibition of transferable TMexCD1-TOprJ1 efflux pump.

**英文摘要原文：**
Recent emergence and dissemination of plasmid-borne tmexCD1-toprJ1 tigecycline resistance threatens the efficacy of tigecycline as a "last-resort" defense against bacterial infections. Here, we report two cryo-EM structures of TMexCD1-TOprJ1 alone and in complex with its NMP inhibitor, and both are determined at the resolutions of 2.97 Å and 3.0 Å, respectively. The symmetry of overall architecture explains how the tripartite organization adopts a 3:6:3 protomer stoichiometry (TOprJ1: TMexC1: TMexD1) to assemble an elongated, rod-like pump spanning bacterial double membranes. The periplasmic TMexC1 adaptor bind the trimeric TOprJ1 funnel via a universal "tip-to-tip" contact, and bridges the bottom TMexD1 engine by extensive interactions. A unique form of resting (R) states is observed for TMexD1 trimer. Besides two binding-interfaces of TMexC1 with TOprJ1 and TMexD1, we characterize a substrate/inhibitor-loading cavity. Collectively, these findings constitute molecular bases for assembly and inhibition of transferable TMexCD1-TOprJ1 machinery, and benefit developing next-generation of antimicrobials targeting functional efflux pump.

**中文摘要译文：**
近期，由质粒携带的tmexCD1-toprJ1基因介导的替加环素耐药性的出现和传播，威胁了替加环素作为对抗细菌感染“最后一道防线”的疗效。本研究中，我们报道了TMexCD1-TOprJ1单独及其与NMP抑制剂复合物的两个冷冻电镜结构，分辨率分别为2.97Å和3.0Å。其整体结构的对称性揭示了该三组分复合体如何以3:6:3（TOprJ1: TMexC1: TMexD1）的亚基化学计量比，组装成一个跨越细菌双层膜的细长杆状泵。周质空间的TMexC1接头蛋白通过一种普遍的“顶端对顶端”接触方式与三聚体TOprJ1漏斗结合，并通过广泛的相互作用连接底部的TMexD1引擎。我们观察到TMexD1三聚体呈现出一种独特的静息（R）状态。除了TMexC1与TOprJ1和TMexD1的两个结合界面外，我们还鉴定了一个底物/抑制剂装载腔。总而言之，这些发现为可转移性TMexCD1-TOprJ1机器的组装和抑制提供了分子基础，并有助于开发靶向功能性外排泵的新一代抗菌药物。

### 第二部分 AI 大师评价

该研究利用高分辨率冷冻电镜技术，首次揭示了可转移性质粒介导的替加环素耐药外排泵TMexCD1-TOprJ1的精细三维结构及其与抑制剂的复合物构象。研究关键发现阐明了该泵独特的3:6:3亚基组装模式和跨膜工作机制，并精准定位了底物/抑制剂的结合位点。这项工作不仅为理解细菌耐药性的分子机制提供了关键见解，更重要的是，为开发靶向此类外排泵的新型抗菌药物或抑制剂提供了精确的结构生物学基础，具有重大的临床转化潜力。

---

## 8. 未来十年结节病的治疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41237809](https://pubmed.ncbi.nlm.nih.gov/41237809)
**期刊：** Seminars in respiratory and critical care medicine
**PMID：** 41237809
**DOI：** 10.1055/a-2746-4508

### 第一部分 原文与翻译

**英文原标题：** Treatment of Sarcoidosis Over the Next Decade.

**英文摘要原文：**
Sarcoidosis is an enigmatic, multi-system inflammatory disorder characterized by the formation of non-necrotizing granulomas in affected organs. Sarcoidosis may be self-limited or spontaneously resolve in up to two-thirds of individuals, but 10-30% develop a more chronic syndrome requiring long-term treatment. Most individuals will require treatment at some point during the course of disease. Currently guidelines recommend treatment in those at risk of future morbidity or organ dysfunction and to preserve quality of life. Careful identification of those likely to benefit from treatment is critical, as current agents are cumbersome to monitor and all have adverse effects. There is a lack of validated prognostic markers to identify those at risk for poor outcomes, but identifying characteristic manifestations of severe disease early can assist with treatment planning. While corticosteroids have been central to treatment of sarcoidosis, newer data have challenged the current treatment paradigm of steroids as first line agents. Recent and ongoing clinical trials may provide evidence for individualized approaches centered on shared decision-making with patients, as balancing the benefits of treatment must always be weighed with the potential for toxicity. This paper will provide an update on current treatment paradigms, new therapeutic strategies, and potential novel agents on the horizon while highlighting the existing challenges and barriers to progress.

**中文摘要译文：**
结节病是一种神秘的多系统炎症性疾病，其特征是在受累器官中形成非坏死性肉芽肿。多达三分之二的患者可能表现为自限性或自发缓解，但有10-30%的患者会发展为需要长期治疗的慢性综合征。大多数患者在病程中的某个时间点需要治疗。目前的指南建议对那些有未来发病或器官功能障碍风险的患者进行治疗，以保护其生活质量。仔细识别那些可能从治疗中受益的患者至关重要，因为目前的药物监测繁琐且均有不良反应。目前缺乏经过验证的预后标志物来识别具有不良结局风险的患者，但尽早识别严重疾病的特征性表现有助于治疗规划。虽然皮质类固醇一直是结节病治疗的核心，但新的数据对目前将类固醇作为一线药物的治疗模式提出了挑战。近期及正在进行的临床试验可能为以医患共同决策为中心的个体化方法提供证据，因为必须始终权衡治疗的益处与潜在的毒性。本文将更新当前的治疗模式、新的治疗策略以及即将出现的潜在新药，同时强调现有挑战和进展障碍。

### 第二部分 AI 大师评价

该综述文章系统地探讨了未来十年结节病的治疗策略。文章的核心目的在于总结当前的治疗范式，并展望以个体化治疗和医患共同决策为中心的新兴疗法，特别是对传统一线皮质类固醇治疗地位的挑战。其关键价值在于为临床医生提供了关于结节病治疗策略演变的最新视角，并指出了识别高危患者和开发新型靶向药物的未来研究方向。作为一篇前瞻性综述，它为该领域的临床实践和科研提供了重要的指导和参考。

---

## 9. PIEZO1功能增益性突变除引起铁过载外，还通过扰乱心肌脂质稳态驱动心肌病

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41237237](https://pubmed.ncbi.nlm.nih.gov/41237237)
**期刊：** Science advances
**PMID：** 41237237
**DOI：** 10.1126/sciadv.ady9242

### 第一部分 原文与翻译

**英文原标题：** PIEZO1 gain-of-function mutation drives cardiomyopathy by disrupting myocardial lipid homeostasis besides iron overload.

**英文摘要原文：**
As a mechanosensitive channel, PIEZO1 translates mechanical stretching of cardiomyocytes into Ca signaling, underpinning the Frank-Starling law. This mechanism contributes to compensatory responses in heart failure. However, the relationship between PIEZO1 mutations and the development of cardiomyopathy remains unclear. Acute heart failure complicated with severe myocardial iron deposition was identified in the 31-year-old male proband of PIEZO1 variant. However, PIEZO1 gain-of-function (GOF) mutation D674Y mice and cardiomyocyte-specific  overexpression disrupted cardiac function besides iron overload. Using single-cell RNA sequencing, we observed suppression of lipid metabolism pathways in cardiomyocytes with the PIEZO1 GOF mutation, with forkhead box O3 (FOXO3) as a key mediator in lipid metabolism pathways. Specifically, the PIEZO1 GOF mutation increased Ca levels, leading to calcium- and calmodulin-dependent protein kinase II (CaMKII) activation and subsequent FOXO3 down-regulation. Together, we demonstrate that PIEZO1 GOF mutation contributes to cardiomyopathy by disrupting myocardial lipid metabolism. This study challenges the current clinical focus on iron-related mechanisms in cardiomyopathy and supports PIEZO1 as a potential candidate for future genetic screening for cardiomyopathy.

**中文摘要译文：**
作为一种机械敏感性离子通道，PIEZO1将心肌细胞的机械牵张转化为钙信号，是Frank-Starling定律的分子基础。这一机制有助于心力衰竭时的代偿性反应。然而，PIEZO1突变与心肌病发生发展的关系尚不明确。在一个携带PIEZO1变异的31岁男性先证者中，我们发现其患有急性心力衰竭并伴有严重的心肌铁沉积。然而，PIEZO1功能增益性（GOF）突变D674Y小鼠及心肌细胞特异性过表达PIEZO1不仅引起铁过载，还损害了心脏功能。通过单细胞RNA测序，我们观察到携带PIEZO1 GOF突变的心肌细胞中脂质代谢通路受到抑制，其中叉头框O3（FOXO3）是脂质代谢通路中的一个关键介导因子。具体而言，PIEZO1 GOF突变增加了细胞内钙离子水平，导致钙/钙调蛋白依赖性蛋白激酶II（CaMKII）活化，并继而下调了FOXO3的表达。综上所述，我们证明了PIEZO1 GOF突变通过扰乱心肌脂质代谢来促进心肌病的发生。本研究对当前临床上关注心肌病中铁相关机制的观点提出了挑战，并支持将PIEZO1作为未来心肌病基因筛查的潜在候选靶点。

### 第二部分 AI 大师评价

本研究旨在阐明PIEZO1功能增益性突变导致心肌病的分子机制。研究结合了临床病例、基因工程小鼠模型和单细胞测序技术，发现该突变不仅引起铁过载，更关键的是通过Ca²⁺-CaMKII-FOXO3信号轴下调脂质代谢，从而扰乱心肌脂质稳态。此发现创新性地揭示了独立于铁代谢紊乱的心肌病致病新通路，挑战了传统认知。该成果提示PIEZO1可作为心肌病基因筛查的重要靶点，具有显著的临床转化潜力。

---

速递结束，祝您工作愉快！